Loading
Life sciences · Journal article
Discover Oncology · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. It remains difficult to treat because of its heterogeneity, metastatic potential, and resistance to therapy. Berberine exhibits promising anticancer activity. However, pharmacokinetic and delivery limitations, including poor solubility, low bioavailability, rapid metabolism, and inadequate tumor targeting, may limit its clinical translation. To critically review molecular mechanisms of berberine nano-based delivery strategies, translational challenges, and future perspectives for TNBC treatment. PubMed, Scopus, Web of Science, and Google Scholar searches were performed to identify relevant published studies. This narrative review followed the Scale for the Assessment of Narrative Review Articles (SANRA) framework. The findings from preclinical studies were qualitatively synthesized and critically appraised. This review showed that berberine suppresses TNBC progression by modulating multiple signaling pathways, including PI3K/AKT/mTOR, EGFR/MEK/ERK, NF-κB, STAT3, AMPK, TGF-β, Wnt/β-catenin, and NLRP3. Nanoformulations, including polymeric nanoparticles, lipid-based nanocarriers, dendrimers, micelles, inorganic, hybrid, and stimuli-responsive systems, improved solubility, bioavailability, stability, tumor accumulation, and intracellular delivery. These improvements enhanced therapeutic efficacy. Polymeric and lipid-based nanocarriers demonstrated the greatest translational potential because of their favorable efficacy, biocompatibility, and scalability. However, clinical translation remains limited by insufficient human evidence, safety concerns, manufacturing complexity, regulatory uncertainty, and lack of standardized formulations. Nano-berberine represents a promising strategy for TNBC treatment. Clinical translation will require standardized formulations, safety assessments, scalable production, regulatory alignment, and well-designed clinical trials.